Oral Hemangiomas

Earn CME/CE in your profession:

Continuing Education Activity

Oral hemangiomas are benign tumors that develop in and around the oral cavity due to endothelial cell proliferation. The majority of oral hemangiomas will involute over time and do not require treatment. Medical and surgical therapy is available if these tumors persist into adulthood or interfere with speech, swallowing, or the airway. This activity reviews the evaluation and management of oral hemangiomas and highlights the role of the healthcare team in improving care for patients with this condition.


  • Review the epidemiology of oral hemangiomas.
  • Describe the common physical exam findings associated with oral hemangiomas.
  • Outline the treatment considerations for patients with oral hemangiomas.
  • Explain the importance of collaboration and communication amongst the interprofessional team to enhance care coordination for patients affected by oral hemangiomas.


Oral hemangiomas (OHs) are benign tumors that develop due to endothelial cell proliferation and occur in and around the oral cavity. While 60 to 70 percent of hemangiomas occur in the head and neck region, OHs are relatively rare and most frequently involve the lips, tongue, buccal mucosa, and palate. OHs have also been noted in the mandible and maxilla (central hemangiomas) and within the masseter and other muscles of mastication (intramuscular hemangiomas).

The term “hemangioma” and “vascular malformation” have often been used interchangeably, creating significant confusion in both the clinical setting and in the literature. As Mulliken and Glowacki proposed in their 1982 classification system, “hemangiomas” are true neoplasms characterized by proliferation and increased rates of endothelial cell turnover, while “vascular malformations” are localized anomalies due to defects in vascular morphogenesis with normal rates of cell turnover.

Clinically, hemangiomas can be classified as infantile (formerly called juvenile or strawberry) or congenital. Infantile hemangiomas (IHs) develop during the first 2 months of life and demonstrate rapid proliferation between 6 and 12 months of age, followed by a period of slow involution. Most IHs will spontaneously regress between 6 and 9 years of age. In contrast, congenital hemangiomas (CHs) are present at birth, do not exhibit a proliferative phase, and either rapidly involute or not at all. The majority of hemangiomas will completely involute, with 10%-20% persisting into adolescence or adulthood. While medical, interventional, and surgical regimens are available, there is no standardized treatment for OHs. Due to myriad potential complications, treatment of OHs is typically not pursued unless functional impairment exists.[1][2][3]


The cause of OHs is poorly understood, although genetic mutations, embolic phenomenon, and hormones may play a prominent role in development. One hypothesis suggests that OHs are due to embolic placental endothelial cells, which enter the fetal circulation following trauma or some other cellular stressor and serve as stem cells. This explanation is consistent with studies that demonstrate that chorionic villus sampling increases the risk of hemangiomas. Another theory is that spontaneous, or inherited, loss-of-function mutations on chromosome 5q lead to the constitutive activation of angiogenesis, resulting in hemangioma formation. A third hypothesis is that hemangiomas develop due to the upregulation of vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1) production by nearby cells in response to hypoxic stressors. However, none of these hypotheses address the female predominance of hemangiomas or the predilection of these vascular tumors for the head and neck.[4]


Oral hemangiomas affect up to 6.4% of infants, with limited data available to estimate prevalence in older age groups. These tumors are more common on the ventral surface of the tongue, as opposed to oral vascular malformations, which are more prevalent on the lips. OHs have a 3:1 female-to-male predominance and are more common in Whites. Infants who are premature, twins or triplets, have low birth weight (less than 1 kilogram), or who are born to older mothers are more likely to develop OHs.[5]


Hemangiomas are speculated to develop through a combination of angiogenesis (the growth of new vessels from established vessels) and vasculogenesis (the novel formation of vessels from stem, or progenitor, cells). Three characteristic stages of growth have been noted: (1) endothelial cell proliferation, (2) rapid growth, and (3) spontaneous involution. Growth begins after progenitor cells, possibly originating from the placenta, move through the circulation and implant on distant regions of the body.

During the proliferative phase, endothelial cells rapidly multiply, stimulated by factors such as VEGF, basic fibroblast growth factor (bFGF), and transforming growth factor-beta (TGF-beta). Estradiol-17 beta-receptors are also uniquely present in the cytoplasm of endothelial cells during this first phase, although their role in proliferation is not completely understood. During the rapid growth phase, the number of endothelial cells stabilizes, and the cells themselves will enlarge, leading to an overall increase in structure size.

Lastly, spontaneous involution occurs when the vessels decline in number, and endothelial cells are replaced by fat, fibroblasts, and connective tissue. The inciting event for involution is unclear but may involve the Notch pathway, which includes transmembrane Notch receptors and its ligands (delta and jagged).[6][7]


During the proliferative phase of OH development, the vessels are small, disorganized, and contain tiny lumens, which can be difficult to visualize on microscopic examination. In contrast, the endothelial cells are wide and contain prominent basement membranes composed of alpha-smooth muscle actin.

In the rapid growth stage, the endothelial cells enlarge, their basement membranes become less prominent, and the number of cells stabilizes. As the vessels mature and enter the spontaneous involution phase, the endothelial cells lose their contents and become flattened, with certain cells undergoing apoptosis to be replaced by fat, fibroblasts, and connective tissue.

While endothelial cells during any phase of OH growth will demonstrate CD31, von Willebrand factor, and urokinase, cells during the involution phase uniquely demonstrate Fc gamma receptors (FcII), Lewis Y antigen (LeY), and merosin. Immunohistochemistry can be used to distinguish not only the growth phase but the type of lesion, as infantile hemangiomas will exhibit positivity for glucose transporter 1 (GLUT-1), which is not present in congenital hemangiomas or vascular malformations.[8][9]

History and Physical

While hemangiomas of the head and neck are relatively common, the presence of these lesions in the oral cavity is rare and can thus lead to clinical uncertainty. OHs will most often involve the lips, tongue, buccal mucosa, and palate. Patients, or their parents, may note changes in these structures over time as they proliferate, stabilize, and (possibly) regress. During the first three to nine months of life, OHs can demonstrate rapid growth, followed by a period of stabilization at about one year-of-age. Most OHs will then enter into a phase of spontaneous involution, with 85% to 90% of lesions resolving within the next four years.

Hemangiomas of the lower lip have been noted to show lower rates of involution than lesions located elsewhere. Also, if patients have more than one OH, the behavior of one structure is not predictive of the rates of progression or involution of another. Most OHs are painless and asymptomatic and are diagnosed on routine physical examination. However, patients with central (intraosseous) or intramuscular hemangiomas may present with gingival bleeding (spontaneous or post-traumatic), excessive bleeding after dental procedures, or increased mobility of the teeth.

OHs are soft, compressible masses that can present with significant variation depending on location and depth. Superficial lesions may demonstrate a prominent red hue and be described as lobulated, sessile, or pedunculated. Deeper lesions are often more difficult to visualize and may appear as a soft blue or violent discoloration distinct from surrounding mucosa. Diascopy, the blanching of an oral lesion following compression with a finger or glass slide, is a physical examination maneuver that can be used to distinguish vascular lesions (blanching) from purpura (non-blanching). OHs are also noted to become more prominent and darken when lowering the head and/or compressing the abdomen.[10][11]


Hemangiomas within the oral mucosa can be diagnosed clinically, without the need for lab work or additional imaging. If treatment is desired, a color-doppler ultrasound is often the first-line imaging modality as it can readily provide morphological and vascular information while being cost-effective, non-invasive, and without the risk of radiation. If an intraosseous or intramuscular hemangioma is suspected, a contrast-enhanced MRI would be the imaging modality of choice and is considered superior to CT scan. Generally, a biopsy of OHs is avoided due to a high risk of bleeding. However, a biopsy would be recommended if a malignant process is suspected.[12]

Treatment / Management

Most oral hemangiomas will not require treatment due to their benign presentation and a high rate of complete involution over time. However, for OHs that present with impairment in speech, swallowing, or airway compromise, and for the 10% to 20% of lesions that persist into adolescence or adulthood, treatment is recommended. Current treatment options are divided into two categories: medical and surgical (or interventional).

Beta-blockers, such as propranolol, are the mainstay of medical treatment for OHs. The mechanism is unclear but has been suggested to include local vasoconstriction and triggering of apoptosis in endothelial cells. Patients are typically initiated on a regimen of propranolol 2-3 milligrams per kilogram per day divided into three doses, with improvement in OH appearance noted within 1-2 days after therapy begins. Throughout the duration of beta-blocker therapy, which may be up to 6 months, patients should be monitored for side effects, including bradycardia, hypotension, hypoglycemia, and bronchospasm.

Oral steroids are another option in the treatment of OHs but are not preferred to beta-blockers due to their unfavorable side effect profile. Prednisone has been most frequently studied for OH treatment and can be continued for up to four months. Varying dosing regimens are mentioned in the literature, with 2 milligrams per kilogram per day used in some studies and 20 to 30 milligrams per day used in others. It is generally agreed that if no change in the OH is noted within 2 weeks, prednisone therapy should be discontinued.

Patients, especially children, should be monitored while on steroid therapy for the development of hypertension, persistent hyperglycemia, changes in mood, and growth retardation. For patients with OHs resistant to beta-blockers and steroids, interferon-alpha has been studied with some success but is generally not preferred due to the risk of spastic diplegia, neutropenia, thrombocytopenia, and hepatic toxicity. For patients who do not respond to medical therapy, or present with compromise in function, interventional or surgical options can be offered.

Surgical resection offers definitive treatment for OH and may be preferred for smaller lesions located on the lips and buccal mucosa. Resection would not be preferred for large lesions on the tongue as significant removal of tissue can result in chronic impairment of speech and swallowing. Sclerotherapy, in which a foreign agent (such as 3% sodium tetradecyl sulfate or ethanolamine oleate) is injected into one of the major vessels of an OH, leading to endothelial damage and obliteration of the lumen, is an evolving treatment modality for these lesions. Thus far, studies have demonstrated favorable results with minor adverse reactions following sclerotherapy treatment, but the risk of thrombosis with embolization does remain.[13][14][15][16]

Differential Diagnosis

When diagnosing oral hemangiomas, the following conditions should also be considered:

  • Vascular malformation
  • Vascular ectasia
  • Pyogenic granuloma
  • Granular cell myoblastoma
  • Angiomyolipoma
  • Angiosarcoma
  • Hemangiosarcoma
  • Kaposi’s sarcoma
  • Lymphangioma


Oral hemangiomas have an overall favorable prognosis, as these lesions are benign, and only a minority (10% to 20%) will require treatment. Intraosseous, especially mandibular, hemangiomas are associated with higher morbidity due to increased risk of spontaneous and post-procedural hemorrhage.


Complications associated with OHs depend on the size and location of the lesion and may include:

  • Ulceration (the most common complication)
  • Hemorrhage
  • Dysphagia and failure to thrive
  • Speech impairment
  • Airway compromise


Generally, consultation for the management of OH is not required. If advanced treatment is sought, a referral to interventional radiology or oral and maxillofacial surgery can be placed.

Deterrence and Patient Education

For most OHs, patients and their families should be provided with reassurance that these lesions are benign and demonstrate a high rate of involution over time. For patients placed on medical therapy, education and regular follow-up are necessary to monitor for drug side effects.

Enhancing Healthcare Team Outcomes

OHs are typically diagnosed in children, and the majority of these lesions will involute over time. Primary clinicians have a key role in reassuring patients, and their parents, about the benign nature of OHs and maintaining regular follow-up appointments for monitoring. If medical therapy is initiated, pharmacists will be helpful in providing education about drug side effects. If sclerotherapy or surgical resection is required, interventional radiologists or oral and maxillofacial surgeons, respectively, will be involved to assess patients as surgical candidates, provide information about the risks and benefits of these procedures, and provide post-procedural monitoring and education. [Level II]



Yana Puckett


8/8/2023 1:42:15 AM



George A, Mani V, Noufal A. Update on the classification of hemangioma. Journal of oral and maxillofacial pathology : JOMFP. 2014 Sep:18(Suppl 1):S117-20. doi: 10.4103/0973-029X.141321. Epub     [PubMed PMID: 25364160]


Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plastic and reconstructive surgery. 1982 Mar:69(3):412-22     [PubMed PMID: 7063565]


Nayak SK, Nayak P. Intramuscular hemangioma of the oral cavity - a case report. Journal of clinical and diagnostic research : JCDR. 2014 Aug:8(8):ZD41-2. doi: 10.7860/JCDR/2014/8305.4756. Epub 2014 Aug 20     [PubMed PMID: 25302283]

Level 3 (low-level) evidence


Marchuk DA, Pathogenesis of hemangioma. The Journal of clinical investigation. 2001 Mar;     [PubMed PMID: 11254664]


Corrêa PH, Nunes LC, Johann AC, Aguiar MC, Gomez RS, Mesquita RA. Prevalence of oral hemangioma, vascular malformation and varix in a Brazilian population. Brazilian oral research. 2007 Jan-Mar:21(1):40-5     [PubMed PMID: 17384854]


Kamala KA, Ashok L, Sujatha GP. Cavernous hemangioma of the tongue: A rare case report. Contemporary clinical dentistry. 2014 Jan:5(1):95-8. doi: 10.4103/0976-237X.128680. Epub     [PubMed PMID: 24808705]

Level 3 (low-level) evidence


Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. The British journal of dermatology. 2013 Jul:169(1):12-9. doi: 10.1111/bjd.12435. Epub     [PubMed PMID: 23668474]


Steiner JE,Drolet BA, Classification of Vascular Anomalies: An Update. Seminars in interventional radiology. 2017 Sep;     [PubMed PMID: 28955111]


Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. The Journal of clinical investigation. 1994 Jun:93(6):2357-64     [PubMed PMID: 7911127]


Dilsiz A, Aydin T, Gursan N. Capillary hemangioma as a rare benign tumor of the oral cavity: a case report. Cases journal. 2009 Sep 9:2():8622. doi: 10.1186/1757-1626-0002-0000008622. Epub 2009 Sep 9     [PubMed PMID: 20181211]

Level 3 (low-level) evidence


da Silva WB, Ribeiro AL, de Menezes SA, de Jesus Viana Pinheiro J, de Melo Alves-Junior S. Oral capillary hemangioma: a clinical protocol of diagnosis and treatment in adults. Oral and maxillofacial surgery. 2014 Dec:18(4):431-7. doi: 10.1007/s10006-013-0436-z. Epub 2013 Nov 22     [PubMed PMID: 24263242]


Gianfranco G,Eloisa F,Vito C,Raffaele G,Gianluca T,Umberto R, Color-Doppler ultrasound in the diagnosis of oral vascular anomalies. North American journal of medical sciences. 2014 Jan;     [PubMed PMID: 24678469]


Nguyen HP, Pickrell BB, Wright TS. Beta-blockers as therapy for infantile hemangiomas. Seminars in plastic surgery. 2014 May:28(2):87-90. doi: 10.1055/s-0034-1376259. Epub     [PubMed PMID: 25045334]


Zhang L, Zheng JW, Yuan WE. Treatment of alarming head and neck infantile hemangiomas with interferon-α2a: a clinical study in eleven consecutive patients. Drug design, development and therapy. 2015:9():723-7. doi: 10.2147/DDDT.S67682. Epub 2015 Feb 4     [PubMed PMID: 25678777]


Bonet-Coloma C, Mínguez-Martínez I, Palma-Carrió C, Galán-Gil S, Peñarrocha-Diago M, Mínguez-Sanz JM. Clinical characteristics, treatment and outcome of 28 oral haemangiomas in pediatric patients. Medicina oral, patologia oral y cirugia bucal. 2011 Jan 1:16(1):e19-22     [PubMed PMID: 20711165]


Stuepp RT, Scotti FM, Melo G, Munhoz EA, Modolo F. Effects of sclerosing agents on head and neck hemangiomas: A systematic review. Journal of clinical and experimental dentistry. 2019 Nov:11(11):e1033-e1044. doi: 10.4317/jced.56143. Epub 2019 Nov 1     [PubMed PMID: 31700578]

Level 1 (high-level) evidence